Viewing Study NCT03657160


Ignite Creation Date: 2025-12-25 @ 2:01 AM
Ignite Modification Date: 2026-02-25 @ 12:55 AM
Study NCT ID: NCT03657160
Status: COMPLETED
Last Update Posted: 2023-06-06
First Post: 2018-08-30
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
Sponsor: Millennium Pharmaceuticals, Inc.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hematopoietic Stem Cells View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Drug Therapy View